Literature DB >> 15295781

Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells.

John J Arnold1, Fakhrul Ahsan, Elias Meezan, Dennis J Pillion.   

Abstract

The effect of tetradecylmaltoside (TDM) on nasal peptide drug absorption was assessed with four peptides of distinct molecular size: insulin (5.7 kDa), leptin (16 kDa), somatropin (22.1 kDa), and epoetin alfa (30.4 kDa). The nasal uptake of the smallest peptides, insulin and leptin, was significantly increased at a TDM concentration of only 0.06%. The uptake of somatropin was significantly increased when concentrations of 0.125% or more were used. The uptake of the largest peptide, epoetin alfa, was not significantly increased, in the presence of 0.125-0.5% TDM. Light microscopy revealed that formulations containing 0.125% TDM caused moderate alterations in nasal epithelial cell morphology, while higher concentrations of TDM (0.5%), caused more extensive morphological changes. Following treatment with 0.125% TDM, the distribution of cilia was altered and the number of pinocytotic vesicles was increased, at a time that correlated with increased nasal absorption of insulin. Consistent with these findings, FITC-insulin applied nasally in the absence of TDM did not enter nasal epithelial cells, whereas FITC-insulin co-administered with 0.125% TDM was internalized into the cells, with a uniform distribution, consistent with transcellular movement of the peptide through the cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295781     DOI: 10.1002/jps.20123

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Absorption enhancers: applications and advances.

Authors:  Bruce J Aungst
Journal:  AAPS J       Date:  2011-11-22       Impact factor: 4.009

2.  High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers.

Authors:  Edward T Maggio; Dennis J Pillion
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

3.  Nasal administration of leptin dose-dependently increases dopamine and serotonin outflow in the rat nucleus accumbens.

Authors:  Sonya Neto; Ramya Varatharajan; Kevin Joseph; Andreas Moser
Journal:  J Neural Transm (Vienna)       Date:  2016-07-13       Impact factor: 3.575

4.  Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model.

Authors:  Bettina Buchthal; Ursula Weiss; Hilmar Bading
Journal:  Mol Ther       Date:  2018-07-23       Impact factor: 11.454

5.  CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.

Authors:  Andrew L Lewis; Faron Jordan; Lisbeth Illum
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

6.  Nasal absorption of mixtures of fast-acting and long-acting insulins.

Authors:  Dennis J Pillion; Michael D Fyrberg; Elias Meezan
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

7.  Nasally delivered VEGFD mimetics mitigate stroke-induced dendrite loss and brain damage.

Authors:  Daniela Mauceri; Bettina Buchthal; Thekla J Hemstedt; Ursula Weiss; Christian D Klein; Hilmar Bading
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-30       Impact factor: 11.205

8.  Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease.

Authors:  Carmen M Fernandez-Martos; Rachel A K Atkinson; Meng I Chuah; Anna E King; James C Vickers
Journal:  Alzheimers Dement (N Y)       Date:  2016-12-20

9.  The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS).

Authors:  Agueda Ferrer-Donato; Ana Contreras; Paloma Fernandez; Carmen M Fernandez-Martos
Journal:  Brain Behav       Date:  2021-12-21       Impact factor: 2.708

10.  A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies.

Authors:  Hsih-Yin Tan; Sofie Trier; Ulrik L Rahbek; Martin Dufva; Jörg P Kutter; Thomas L Andresen
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.